This content is intended only for healthcare professionals outside of the USAcceptDecline
touchCONGRESS Expert Opinions
Length of activity: 60 minutes Prof. Angelo Antonini, Prof. Ray Chaudhuri, Dr. Rick Helmich and Prof. Heinz Reichmann discuss data for advanced Parkinson's disease from key congresses in 2018.
THIS CONTENT IS AVAILABLE FOR FREE TO REGISTERED USERS You are not currently logged in. LOGIN or REGISTER to access this content
LOGIN or REGISTER to access this content
Benefits:
Immediate, and unrestricted free access to all resources
Earn AMA PRA Category 1 Credits™ for completing accredited activities
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Watch a series of internationally renowned clinical specialists from Europe discuss pivotal data for Parkinson’s disease from key neurology congresses throughout 2018 and consider how these findings may affect clinical practice.
The potential implications of these data for optimizing outcomes for patients with advanced Parkinson’s disease are explored from both global and regional perspectives.
The information in this activity is intended for neurologists, nurses and other healthcare professionals involved in the treatment of patients with Parkinson’s disease.
Learning Objectives
After watching these touchCONGRESS Expert Opinions from key neurology congresses during 2018, you should be able to:
Summarize the latest clinical data for emerging treatment options and treatment delivery systems for the management of motor and non-motor symptoms of Parkinson’s disease.
Discuss the use of biomarkers for the early identification of Parkinson’s disease, and to facilitate the use of neuroprotective agents.
Describe the use of emerging targeted agents and therapeutic strategies to manage treatment side effects and maintain patient quality of life.
Please feedback on this touchCONGRESS Expert Opinions on the following: (scale 1-5, 1 strongly disagree; 5 strongly agree).